Journal: European Journal of Medical Research

Article Title: Overexpression of the lncRNA TUG1 regulates high-glucose-induced endocytic clearance dysfunction in HLSECs via the Wnt/β-catenin signaling pathway

doi: 10.1186/s40001-025-03722-w

Figure Lengend Snippet: a–c Relative mRNA expression of the lncRNA TUG1, β-catenin, and cyclin D1 in the different groups. d WB bands of target proteins. e–g Relative protein expression of lncRNA TUG1, β-catenin, and cyclin D1 in each group. h Immunofluorescence staining showing β-catenin localization in HLSECs under different intervention conditions. i Quantitative analysis of β-catenin nuclear translocation (N/C ratio) measured by immunofluorescence (repeated-measures one-way ANOVA followed by Tukey’s post-hoc test, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, n = 3, scale bar = 50 μm for all panels)

Article Snippet: GAPDH (bsm-33033 M), antibodies against β-catenin (bsm-55526R), and p-β-catenin (bs-12854R), antibodies against Cyclin D1 (bs-0623R), antibodies against CAV-1 (bsm-60809R), and HRP-conjugated secondary antibodies were purchased from Bioss Biotechnology Co., Ltd. (Beijing, China).

Techniques: Expressing, Immunofluorescence, Staining, Translocation Assay

Journal: Journal of translational medicine

Article Title: METTL3 regulates Ambra1 expression in an m6A-YTHDF2-dependent manner to promote mantle cell lymphoma progression.

doi: 10.1186/s12967-025-06647-4

Figure Lengend Snippet: Fig. 8 METTL3/YTHDF2/Ambra1 promotes MCL progression. (A) Representative images of tumors from each group on day 28. (B-C) Changes in tumor size and weight in the indicated groups. (D) METTL3 and Ambra1 mRNA and protein expression in the tumor tissues of the indicated groups. (E) Immu noblots showing the expression of Bcl2, BAX, cleaved caspase-3, and PARP in the tumor tissues. (F-G) Representative IHC images showing expression of cyclin D1, CDK4, and CDK6 in the tumor tissues. n = 5, *P < 0.05 vs. sh-NC + sh-NC group, #P < 0.05 vs. sh-METTL3 + sh-NC group, &P < 0.05 vs. sh-NC + sh- Ambra1 group

Article Snippet: After blocking with 5% BSA, the sections were incubated overnight with rabbit polyclonal antibodies against cyclin D1 (AWA10518, Abiowell), CDK4 (11026-1-AP, ProteinTech), and CDK6 (14052-1-AP, ProteinTech) (dilution 1:200) at 4 °C.

Techniques: Expressing

Journal: Molecular Medicine

Article Title: PELI2 inhibits colorectal cancer development through MAPK signaling pathway

doi: 10.1186/s10020-025-01294-3

Figure Lengend Snippet: Knockdown of PELI2 increased the proliferation, migration and apoptosis of colorectal cancer cells in vitro. A RT-qPCR was used to determine the mRNA levels of PELI2 in six human CRC cell lines and the normal colon cell line NCM460. B Western blot was used to determine the expression levels of PELI2 in human CRC cell lines and the normal colon cell line NCM460. C , D The knockdown efficiency of PELI2 in HCT116 cells and SW480 cells was detected by RT-qPCR ( C ) and Western blot ( D ). E The cell viability increased after PELI2 knockdown in HCT116 cells and SW480 cells. F Colony Formation Assay of shControl and shPELI2 HCT116 and SW480 cells. Representative images are shown on the top, and statistical graph is shown on the down. G Scratch assay of shControl and shPELI2 HCT116 and SW480 cells. Representative images are shown on the left, and statistical graph at 24 h and 48 h is shown on the right. H Transwell assay of shControl and shPELI2 HCT116 and SW480 cells. Representative images are shown on the left, and statistical graph is shown on the right. I Protein expression levels of BAX, BCL2, MMP9, Cyclin D1, and Cyclin B1 were verified in shControl and shPELI2 HCT116 and SW480 cells. All experiments were biological replicates and were repeated at least three times. Error bars showed standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The following antibodies were used in our study: Anti-PELI2 Polyclonal antibody (Cat# 16097-1-AP, Proteintech), Anti-β-actin antibody (Cat# A5441, Sigma), Anti-Myc Antibody (Cat# sc-40, Santa Cruz), Anti-BAX Polyclonal antibody (Cat# 50599-2-Ig, Proteintech), Anti-BCL2 Polyclonal antibody (Cat# 26593-1-AP, Proteintech), Anti-MMP9 Polyclonal antibody (Cat# 10375-2-AP, Proteintech), Anti-Cyclin D1 Polyclonal antibody (Cat# 26939-1-AP, Proteintech), Anti-Cyclin B1 Polyclonal antibody (Cat# 55004-1-AP, Proteintech), Anti-MEK1/2 Polyclonal antibody (Cat# 11049-1-AP, Proteintech), Anti-Phospho-MEK1/2 (Ser217/221) antibody (Cat# 9121, CST), Anti-p44/42 MAPK (Erk1/2) (137 F5) Rabbit mAb (Cat# 4695, CST), Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cat# 9101, CST),Anti-E-cadherin antibody (Cat# TA0131,Abmart), Anti-N Cadherin antibody (Cat# T55015 ,Abmart), Anti-mouse HRP (Cat# ZB-2305, Zsbio), Anti-rabbit HRP (Cat# ZB-2301, Zsbio).

Techniques: Knockdown, Migration, In Vitro, Quantitative RT-PCR, Western Blot, Expressing, Colony Assay, Wound Healing Assay, Transwell Assay

Journal: Molecular Medicine

Article Title: PELI2 inhibits colorectal cancer development through MAPK signaling pathway

doi: 10.1186/s10020-025-01294-3

Figure Lengend Snippet: Overexpression of PELI2 decreased the proliferation, migration and apoptosis of colorectal cancer cells in vitro. A , B Overexpression efficiency of PELI2 in HCT116 cells and SW480 cells was detected by RT-qPCR ( A ) and Western blot ( B ). C The cell viability reduced after PELI2 overexpression in HCT116 cells and SW480 cells. D Colony Formation Assay of Vector and oePELI2 HCT116 and SW480 cells. Representative images are shown on the left, and statistical graph is shown on the right. E Scratch assay of Vector and oePELI2 HCT116 and SW480 cells. Representative images are shown on the left, and statistical graph at 24 h and 48 h is shown on the right. F Transwell assay of Vector and oePELI2 HCT116 and SW480 cells. Representative images are shown on the left, and statistical graph is shown on the right. G Protein expression levels of BAX, BCL2, MMP9, Cyclin D1, and Cyclin B1 were verified in Vector and oePELI2 HCT116 and SW480 cells by Western blot. All experiments were biological replicates and were repeated at least three times. Error bars showed standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The following antibodies were used in our study: Anti-PELI2 Polyclonal antibody (Cat# 16097-1-AP, Proteintech), Anti-β-actin antibody (Cat# A5441, Sigma), Anti-Myc Antibody (Cat# sc-40, Santa Cruz), Anti-BAX Polyclonal antibody (Cat# 50599-2-Ig, Proteintech), Anti-BCL2 Polyclonal antibody (Cat# 26593-1-AP, Proteintech), Anti-MMP9 Polyclonal antibody (Cat# 10375-2-AP, Proteintech), Anti-Cyclin D1 Polyclonal antibody (Cat# 26939-1-AP, Proteintech), Anti-Cyclin B1 Polyclonal antibody (Cat# 55004-1-AP, Proteintech), Anti-MEK1/2 Polyclonal antibody (Cat# 11049-1-AP, Proteintech), Anti-Phospho-MEK1/2 (Ser217/221) antibody (Cat# 9121, CST), Anti-p44/42 MAPK (Erk1/2) (137 F5) Rabbit mAb (Cat# 4695, CST), Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cat# 9101, CST),Anti-E-cadherin antibody (Cat# TA0131,Abmart), Anti-N Cadherin antibody (Cat# T55015 ,Abmart), Anti-mouse HRP (Cat# ZB-2305, Zsbio), Anti-rabbit HRP (Cat# ZB-2301, Zsbio).

Techniques: Over Expression, Migration, In Vitro, Quantitative RT-PCR, Western Blot, Colony Assay, Plasmid Preparation, Wound Healing Assay, Transwell Assay, Expressing